Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.49 |
| ▸ | DHFR | P00374 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | RARB | P10826 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8322856 | 1.00 | DPP4 (0.59) | DPP4CHRM2DRD1KDM4ELMNA | |
| SCHEMBL8323268 | 1.00 | DPP4 (0.59) | DPP4CHRM2DRD1KDM4ELMNA | |
| SCHEMBL9572096 | 0.95 | DPP4 (0.62) | DPP4CHRM2DRD1KDM4ELMNA | |
| SCHEMBL8325094 | 0.90 | DPP4 (0.64) | DPP4CHRM2DRD1KDM4ELMNA | |
| SCHEMBL8322847 | 0.87 | DPP4 (0.62) | DPP4CHRM2DRD1KDM4ELMNA | |
| SCHEMBL8775460 | 0.86 | DPP4 (0.64) | DPP4CHRM2DRD1KDM4ELMNA | |
| SCHEMBL8322844 | 0.85 | DPP4 (0.63) | DPP4CHRM2DRD1KDM4ELMNA | |
| SCHEMBL10377708 | 0.85 | DPP4 (0.66) | DPP4CHRM2DRD1KDM4ELMNA | |
| SCHEMBL10377719 | 0.84 | DPP4 (0.65) | DPP4CHRM2DRD1KDM4ELMNA | |
| SCHEMBL10377337 | 0.84 | DPP4 (0.65) | DPP4CHRM2DRD1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120093917-A1 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2012-04-19 | — | — | US | claimed |
| WO-2010114919-A2 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | STC.UNM (US) | 2010-10-07 | — | — | WO | claimed |
| EP-0641339-B1 | AZASPIRO QUINOLONE ANTIBACTERIAL AGENTS | PFIZER (US) | 1999-09-15 | — | — | EP | claimed |
| US-5407943-A | Azaspiro quinolone antibacterial agents | PFIZER INC. (US) | 1995-04-18 | — | — | US | claimed |
| EP-0641339-A1 | AZASPIRO QUINOLONE ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 1995-03-08 | — | — | EP | claimed |
| WO-1992022550-A1 | AZASPIRO QUINOLONE ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 1992-12-23 | — | — | WO | claimed |
| US-20120093917-A1 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2012-04-19 | — | — | US | disclosed |
| EP-0641339-B1 | AZASPIRO QUINOLONE ANTIBACTERIAL AGENTS | PFIZER (US) | 1999-09-15 | — | — | EP | disclosed |
| US-5407943-A | Azaspiro quinolone antibacterial agents | PFIZER INC. (US) | 1995-04-18 | — | — | US | disclosed |
| EP-0641339-A1 | AZASPIRO QUINOLONE ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 1995-03-08 | — | — | EP | disclosed |
| EP-0550016-A1 | Novel quinolone carboxylic acid derivatives and processes for preparing same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1993-07-07 | — | — | EP | disclosed |
| WO-1992022550-A1 | AZASPIRO QUINOLONE ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 1992-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093917-A1 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | RNASE1, DCLRE1B, FEN1 | DPP4 1787/4885CHRM2 4883/4885DRD1 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.